|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHN1 |
Gene summary for CHN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHN1 | Gene ID | 1123 |
| Gene name | chimerin 1 | |
| Gene Alias | ARHGAP2 | |
| Cytomap | 2q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P15882 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1123 | CHN1 | HTA12-15-2 | Human | Pancreas | PDAC | 4.06e-02 | 2.64e-01 | 0.2315 |
| 1123 | CHN1 | HTA12-23-1 | Human | Pancreas | PDAC | 5.20e-08 | 7.01e-01 | 0.3405 |
| 1123 | CHN1 | HTA12-25-1 | Human | Pancreas | PDAC | 3.64e-05 | 4.50e-01 | 0.313 |
| 1123 | CHN1 | HTA12-26-1 | Human | Pancreas | PDAC | 5.25e-22 | 8.69e-01 | 0.3728 |
| 1123 | CHN1 | HTA12-29-1 | Human | Pancreas | PDAC | 2.01e-48 | 9.40e-01 | 0.3722 |
| 1123 | CHN1 | HTA12-32-1 | Human | Pancreas | PDAC | 4.65e-02 | 6.19e-01 | 0.3624 |
| 1123 | CHN1 | ATC09 | Human | Thyroid | ATC | 2.26e-06 | 2.46e-01 | 0.2871 |
| 1123 | CHN1 | ATC11 | Human | Thyroid | ATC | 7.49e-03 | 2.46e-01 | 0.3386 |
| 1123 | CHN1 | ATC12 | Human | Thyroid | ATC | 4.51e-33 | 7.77e-01 | 0.34 |
| 1123 | CHN1 | ATC13 | Human | Thyroid | ATC | 2.37e-16 | 3.00e-01 | 0.34 |
| 1123 | CHN1 | ATC1 | Human | Thyroid | ATC | 1.52e-06 | 2.72e-01 | 0.2878 |
| 1123 | CHN1 | ATC2 | Human | Thyroid | ATC | 4.44e-15 | 1.19e+00 | 0.34 |
| 1123 | CHN1 | ATC3 | Human | Thyroid | ATC | 6.22e-03 | 2.04e-01 | 0.338 |
| 1123 | CHN1 | ATC4 | Human | Thyroid | ATC | 1.79e-43 | 1.01e+00 | 0.34 |
| 1123 | CHN1 | ATC5 | Human | Thyroid | ATC | 5.92e-17 | 3.25e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
| GO:006156423 | Thyroid | ATC | axon development | 220/6293 | 467/18723 | 6.85e-10 | 1.80e-08 | 220 |
| GO:000740919 | Thyroid | ATC | axonogenesis | 197/6293 | 418/18723 | 5.09e-09 | 1.13e-07 | 197 |
| GO:005105618 | Thyroid | ATC | regulation of small GTPase mediated signal transduction | 141/6293 | 302/18723 | 1.43e-06 | 1.77e-05 | 141 |
| GO:005077011 | Thyroid | ATC | regulation of axonogenesis | 80/6293 | 154/18723 | 1.95e-06 | 2.34e-05 | 80 |
| GO:004308719 | Thyroid | ATC | regulation of GTPase activity | 153/6293 | 348/18723 | 3.24e-05 | 2.68e-04 | 153 |
| GO:00074113 | Thyroid | ATC | axon guidance | 96/6293 | 227/18723 | 3.74e-03 | 1.63e-02 | 96 |
| GO:00974853 | Thyroid | ATC | neuron projection guidance | 96/6293 | 228/18723 | 4.36e-03 | 1.81e-02 | 96 |
| GO:004354715 | Thyroid | ATC | positive regulation of GTPase activity | 106/6293 | 255/18723 | 4.58e-03 | 1.89e-02 | 106 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHN1 | SNV | Missense_Mutation | c.673T>A | p.Phe225Ile | p.F225I | P15882 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| CHN1 | SNV | Missense_Mutation | c.394N>C | p.Glu132Gln | p.E132Q | P15882 | protein_coding | tolerated(0.05) | benign(0.347) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CHN1 | SNV | Missense_Mutation | rs775612525 | c.355G>A | p.Asp119Asn | p.D119N | P15882 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A26F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| CHN1 | SNV | Missense_Mutation | novel | c.1227N>T | p.Lys409Asn | p.K409N | P15882 | protein_coding | tolerated(0.1) | benign(0.251) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHN1 | SNV | Missense_Mutation | novel | c.91N>G | p.Arg31Gly | p.R31G | P15882 | protein_coding | tolerated(0.14) | possibly_damaging(0.524) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| CHN1 | SNV | Missense_Mutation | c.508N>A | p.Glu170Lys | p.E170K | P15882 | protein_coding | tolerated(0.91) | benign(0) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | |
| CHN1 | SNV | Missense_Mutation | c.1072G>A | p.Asp358Asn | p.D358N | P15882 | protein_coding | deleterious(0.02) | possibly_damaging(0.88) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CHN1 | SNV | Missense_Mutation | c.685N>A | p.Leu229Ile | p.L229I | P15882 | protein_coding | tolerated(0.09) | probably_damaging(0.98) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CHN1 | SNV | Missense_Mutation | rs373546784 | c.820N>A | p.Val274Met | p.V274M | P15882 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CHN1 | SNV | Missense_Mutation | c.634N>G | p.Thr212Ala | p.T212A | P15882 | protein_coding | deleterious(0.04) | possibly_damaging(0.467) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |